Evidence map›Paper›PMID 42265753›Full record

ArticleJournal of neuroinflammation2026

Ischemic injury triggers a protective microglial phenotype in models of Aβ pathology.

Michael Candlish, Jan Hofmann, Desirée Brösamle, Annika Haessler, Murphy DeMeglio, Angelos Skodras, Georgi Tushev, Eloah S De Biasi, Stefan Günther, René Wiegandt and 14 more

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Michael Candlish *Neurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany.
Jan Hofmann *Neurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany.
Desirée BrösamleDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Annika HaesslerInstitute of Pharmaceutical Technology, Goethe University Frankfurt, Max-von- Laue-Str. 9, Frankfurt am Main, Germany.
Murphy DeMeglioNeurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany.
Angelos SkodrasDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Georgi TushevMax Planck Institute for Brain Research, Max-von-Laue-Str. 4, Frankfurt am Main, Germany.
Eloah S De BiasiNeurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany.
Stefan GüntherMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany.
René WiegandtMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany.
Heidi TheisPlatform for Single Cell Genomics and Epigenomics (PRECISE) at the German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Elena De DomenicoPlatform for Single Cell Genomics and Epigenomics (PRECISE) at the German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Nina Sofia HermannDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Peter BreunigNeurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany.
Christina SauerlandNeurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany.
K Peter R NilssonDepartment of Physics, Chemistry and Biology, Linköping University, Linköping, SE-581 83, Sweden.
Marc D BeyerPlatform for Single Cell Genomics and Epigenomics (PRECISE) at the German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Mario LoosoMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), Bad Nauheim, Germany.
Maike WindbergsInstitute of Pharmaceutical Technology, Goethe University Frankfurt, Max-von- Laue-Str. 9, Frankfurt am Main, Germany.
Sigrun RoeberCenter of Neuropathology and Prion Research, Faculty of Medicine, LMU Munich, Munich, Germany.
Jochen HermsCenter for Neuropathology, Ludwig-Maximilians-University Munich, Munich, Germany.
Jonas J NeherDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Andreas G ChiocchettiDepartment of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
Jasmin K HefendehlNeurovascular Disorders, Institute of Cell Biology and Neuroscience, Biologicum, Goethe University Frankfurt, Max-von-Laue Str. 13, Frankfurt am Main, Germany. hefendehl@bio.uni-frankfurt.de.ORCID http://orcid.org/0000-0001-8994-2536

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microglia are highly plastic cells that are capable of integrating subsequent insults. As the majority of Alzheimer's Disease (AD) patients also show cerebrovascular pathology, we here aimed to dissect the interactions between AD and ischemic brain injury on the microglial response to amyloid beta (Aβ) pathology. Unexpectedly, ischemic stroke in the context of cerebral β-amyloidosis drives the emergence of a neuroprotective microglial phenotype characterized by an ApoE-enriched transcriptional state and enhanced lipid handling. These microglia promote the rapid formation of highly compact Aβ plaques that are relatively inert and strikingly reminiscent of those observed in cognitively resilient AD patients. Our findings thus reveal that the microglial response to Aβ pathology is not a fixed trajectory toward dysfunction, but retains a capacity for beneficial reprogramming when engaged by the appropriate stimulus. Beyond characterizing this comorbid state, our data identify specific molecular pathways, centered on ApoE, complement activation, and lysosomal processing, that may be amenable to therapeutic targeting to promote protective microglial function in AD.

Indexed as

Amyloid beta-PeptidesBrain IschemiaMicrogliaAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsApolipoproteins EDisease Models, AnimalHumansMiceMice, Inbred C57BLMice, TransgenicPhenotypeAmyloid beta-PeptidesAmyloid beta-Protein PrecursorApolipoproteins EAlzheimer’s diseaseCo-morbidityMicrogliaStroke

Identifiers

PMID42265753
PMCPMC13292430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.